Assetmark, Inc Revance Therapeutics, Inc. Transaction History

Assetmark, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$4.65 - $9.31 $9,197 - $18,415	-1,978 Reduced 96.68%	68 $0
Q4 2023 Feb 09, 2024	SELL	$5.81 - $11.2 $7,035 - $13,563	-1,211 Reduced 37.18%	2,046 $17,000
Q3 2023 Oct 27, 2023	BUY	$11.47 - $25.07 $14,463 - $31,613	1,261 Added 63.18%	3,257 $37,000
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $49,301 - $75,069	1,996 New	1,996 $50,000
Q4 2015 Sep 15, 2017	BUY	N/A	14	14 $0

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.